Global Oncology Clinical Trial Market 2021-2025

SKU ID :TNV-19820764 | Published Date: 24-Dec-2021 | No. of pages: 120
• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2020 o Market outlook: Forecast for 2020 - 2025 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Design o Market segments o Comparison by Design o Interventional - Market size and forecast 2020-2025 o Observational - Market size and forecast 2020-2025 o Expanded Access - Market size and forecast 2020-2025 o Market opportunity by Design • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2020-2025 o Europe - Market size and forecast 2020-2025 o Asia - Market size and forecast 2020-2025 o ROW - Market size and forecast 2020-2025 o Key leading countries o Market opportunity By Geographical Landscape o Market drivers o Market challenges o Market trends • Vendor Landscape o Overview o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o F. Hoffmann-La Roche Ltd. o Icon Plc o IQVIA Holdings Inc. o Medpace Holdings Inc. o Merck and Co. Inc. o Novartis AG o Novotech (Australia) Pty Ltd. o Parexel International Corp. o Pivotal S.L.U o Syneos Health Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2020 - 2025 ($ million) • 13: Global market: Year-over-year growth 2020 - 2025 (%) • 14: Five forces analysis 2020 & 2025 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2020 • 21: Design - Market share 2020-2025 (%) • 22: Comparison by Design • 23: Interventional - Market size and forecast 2020-2025 ($ million) • 24: Interventional - Year-over-year growth 2020-2025 (%) • 25: Observational - Market size and forecast 2020-2025 ($ million) • 26: Observational - Year-over-year growth 2020-2025 (%) • 27: Expanded Access - Market size and forecast 2020-2025 ($ million) • 28: Expanded Access - Year-over-year growth 2020-2025 (%) • 29: Market opportunity by Design • 30: Customer landscape • 31: Market share By Geographical Landscape 2020-2025 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2020-2025 ($ million) • 34: North America - Year-over-year growth 2020-2025 (%) • 35: Europe - Market size and forecast 2020-2025 ($ million) • 36: Europe - Year-over-year growth 2020-2025 (%) • 37: Asia - Market size and forecast 2020-2025 ($ million) • 38: Asia - Year-over-year growth 2020-2025 (%) • 39: ROW - Market size and forecast 2020-2025 ($ million) • 40: ROW - Year-over-year growth 2020-2025 (%) • 41: Key leading countries • 42: Market opportunity By Geographical Landscape ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: F. Hoffmann-La Roche Ltd. - Overview • 50: F. Hoffmann-La Roche Ltd. - Business segments • 51: F. Hoffmann-La Roche Ltd. - Key offerings • 52: F. Hoffmann-La Roche Ltd. - Key customers • 53: F. Hoffmann-La Roche Ltd. - Segment focus • 54: Icon Plc - Overview • 55: Icon Plc - Product and service • 56: Icon Plc - Key offerings • 57: Icon Plc - Key customers • 58: Icon Plc - Segment focus • 59: IQVIA Holdings Inc. - Overview • 60: IQVIA Holdings Inc. - Business segments • 61: IQVIA Holdings Inc. - Key offerings • 62: IQVIA Holdings Inc. - Key customers • 63: IQVIA Holdings Inc. - Segment focus • 64: Medpace Holdings Inc. - Overview • 65: Medpace Holdings Inc. - Business segments • 66: Medpace Holdings Inc. - Key offerings • 67: Medpace Holdings Inc. - Key customers • 68: Medpace Holdings Inc. - Segment focus • 69: Merck and Co. Inc. - Overview • 70: Merck and Co. Inc. - Business segments • 71: Merck and Co. Inc. - Key offerings • 72: Merck and Co. Inc. - Key customers • 73: Merck and Co. Inc. - Segment focus • 74: Novartis AG - Overview • 75: Novartis AG - Business segments • 76: Novartis AG - Key offerings • 77: Novartis AG - Key customers • 78: Novartis AG - Segment focus • 79: Novotech (Australia) Pty Ltd. - Overview • 80: Novotech (Australia) Pty Ltd. - Product and service • 81: Novotech (Australia) Pty Ltd. - Key offerings • 82: Novotech (Australia) Pty Ltd. - Key customers • 83: Novotech (Australia) Pty Ltd. - Segment focus • 84: Parexel International Corp. - Overview • 85: Parexel International Corp. - Product and service • 86: Parexel International Corp. - Key offerings • 87: Parexel International Corp. - Key customers • 88: Parexel International Corp. - Segment focus • 89: Pivotal S.L.U - Overview • 90: Pivotal S.L.U - Product and service • 91: Pivotal S.L.U - Key offerings • 92: Pivotal S.L.U - Key customers • 93: Pivotal S.L.U - Segment focus • 94: Syneos Health Inc. - Overview • 95: Syneos Health Inc. - Business segments • 96: Syneos Health Inc. - Key offerings • 97: Syneos Health Inc. - Key customers • 98: Syneos Health Inc. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations
F. Hoffmann-La Roche Ltd., Icon Plc, IQVIA Holdings Inc., Medpace Holdings Inc., Merck and Co. Inc., Novartis AG, Novotech (Australia) Pty Ltd., Parexel International Corp., Pivotal S.L.U, Syneos Health Inc.
  • PRICE
  • $2500
    $5000

Our Clients